With the emergence of experimental therapies for Duchenne muscular dystrophy (DMD), it is fundamental to understand the natural history of this disorder to properly design clinical trials. The aims of this study were to assess the effects produced on motor function by different DMD genotypes and early initiation of glucocorticoids

Main, M

Manzur, AY

Mayhew, A

Mercuri, E

Muntoni, F

on behalf of UK NorthStar Clinical Network, .

Pane, M

Ricotti, V

Ridout, DA

UCL Discovery

English

24month longitudinal data in ambulant boys with Duchenne muscular dystrophy. PLoS One 2013;8:e52512.

6minute walk test in Duchenne MD patients with different mutations: 12month changes.

Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.

Correction: 24 month longitudinal data in ambulant boys with duchenne muscular dystrophy.

Detecting meaningful change using the north star ambulatory assessment in Duchenne muscular dystrophy. Dev Med Child Neurol

Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy.

Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.

Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care.

Dystrophin levels and clinical severity in Becker muscular dystrophy patients.

Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up. Muscle Nerve

Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy. Pediatr Pulmonol 2013;48:912–20.

Eteplirsen for the treatment of Duchenne muscular dystrophy.

Exon skipping and duchenne muscular dystrophy therapy: selection of the most active U1 snRNA antisense able to induce dystrophin exon 51 skipping. Mol Ther 2010;18:1675–82.

Functional changes in Duchenne muscular dystrophy: A 12-month longitudinal cohort study.

Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev

Growth monitoring with the British

Human and Clinical Genetics LUMC.

Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy.

Long-term beneﬁts and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy.

LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy.

minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy.

Moving towards meaningful measurement: rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy.

Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol Ther

Muscular dystrophies.

Naarden, The Netherlands. Neuromuscul Disord 2013;23:682–9.

Neurol Neurosurg Psychiatry 2015;0:1–7. doi:10.1136/jnnp-2014-309405 Neuromuscular5 Cirak

Non Ambulant patients with deletion treatable by exon skipping 53 present a more severe phenotype than the general Duchenne population: neuromuscular disorder.

North Star Ambulatory Assessment,

NorthStar Clinical Network and Database UK. Secondary NorthStar Clinical Network and Database UK

Percent-predicted 6-minute walk distance in Duchenne muscular dystrophy to account for maturational inﬂuences.

Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy.

PTC124 targets genetic disorders caused by nonsense mutations.

Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord

Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. Mol Ther 2012;20:462–7.

SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy.

Stata Statistical Software [program].

Systemic administration of PRO051 in Duchenne’s muscular dystrophy.

The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48weeks from a multicenter study. Muscle Nerve

The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve

The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve 2013;48:32–54.

tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers.

Validation of genetic modiﬁers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants. J Neurol Neurosurg Psychiatry.

The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.